



## Corporate Action Announcement

Citibank, N.A., acting as depositary bank, announces the following:

**Date:** June 1, 2023 **Status:** Final

**Announcement For:** **Merger**

**Company Name:** **Adaptimmune Therapeutics plc**

Security Information	Current Information:	New Information:
----------------------	----------------------	------------------

<b>Company:</b>	Adaptimmune Therapeutics plc
<b>DR Ticker:</b>	ADAP
<b>ORD Ticker:</b>	N/A
<b>CUSIP:</b>	00653A107
<b>Country:</b>	UK
<b>Exchange:</b>	NASDAQ
<b>Ratio (ORD:DR):</b>	6:1
<b>Sponsorship Level:</b>	Sponsored ADR Program
<b>DTC Eligible:</b>	Yes
<b>DR ISIN:</b>	US00653A1079
<b>ORD ISIN:</b>	GB00BVYV1687
<b>Custodian(s):</b>	CITIBANK NA. (LONDON)

### Announcement

[Click Here](#) to see the Notice of Merger of Adaptimmune Therapeutics plc. Adaptimmune Therapeutics plc, CM Merger Sub, Inc., a Delaware corporation and indirect wholly-owned subsidiary of Adaptimmune Therapeutics plc (“[Merger Sub](#)”), and TCR<sup>2</sup> Therapeutics Inc. have entered into an Agreement and Plan of Merger, dated as of March 5, 2023 (the “[Merger Agreement](#)”), pursuant to which Merger Sub is to merge with and into TCR<sup>2</sup> Therapeutics Inc. (the “[Merger](#)”), with TCR<sup>2</sup> Therapeutics Inc. surviving the Merger as a wholly-owned direct subsidiary of CM Intermediate Sub II, Inc., a Delaware corporation and wholly-owned subsidiary of Adaptimmune Therapeutics plc.



## Shareholder Services

Questions may be directed to Shareholder Services toll free at 1-877-248-4237

For further information on Citi's Depository Receipt Services, visit [www.citi.com/dr](http://www.citi.com/dr).